Pena Luis C. 4

What Happened

• Luis C. Pena, President & CEO and a director of Evommune, sold 16,787 shares of EVMN on June 1, 2026. The weighted-average sale price was $22.74 per share, resulting in proceeds of approximately $381,736. This was a sale (not a purchase), which is commonly routine insider liquidity rather than an explicit signal of company outlook.

Key Details

• Transaction date: June 1, 2026
• Transaction type: Sale (open market; multiple trades)
• Shares sold: 16,787
• Weighted-average price: $22.74; individual trade prices ranged from $22.50 to $23.34
• Total proceeds: ~$381,736
• Shares owned after transaction: Not disclosed in this Form 4
• Footnotes: Sale executed under a Rule 10b5-1 trading plan adopted March 2, 2026. The filer can provide a breakdown of shares sold at each price within the stated range upon request.
• Filing timeliness: Report filed June 3, 2026 (this Form 4 does not indicate a late filing)

Context

• The sale was made under a pre-established 10b5-1 plan, which typically authorizes trades at predetermined times or conditions and helps insiders comply with insider-trading rules. Such plan-based sales are generally viewed as routine liquidity transactions rather than direct commentary on company fundamentals.